Sermorelin vs CJC-1295 — GHRH Research

Last updated: May 2026

Sermorelin and CJC-1295 are both synthetic analogs of growth hormone-releasing hormone (GHRH). They bind the same receptor on pituitary somatotroph cells to trigger growth hormone (GH) release. The difference lies in structure, half-life, and research history. Sermorelin is the 29-amino-acid N-end fragment of native GHRH. CJC-1295 is a 30-amino-acid analog with modified residues that resist enzymatic degradation. According to a comparative how the body uses it, test in Growth Hormone. IGF Research (2005), the structural differences between GHRH analogs produce distinct GH pulse patterns. It experts consider when selecting compounds for exact study designs.

Next Level Pharm supplies research-grade Sermorelin. CJC-1295 (No DAC) each tested to at least 99 percent purity by HPLC. Mass spec on every batch. A Certificate of Test ships with every order.

The sections below compare the structure, half-life, receptor pharmacology, GH pulse data. Research applications of sermorelin and CJC-1295 to help experts understand which compound fits which study design.

Key Takeaways

Sermorelin: A 29-amino-acid fragment of native GHRH with a short half-life (under 10 minutes in animal models). It produces pulsatile GH release patterns similar to natural GHRH.
CJC-1295: A 30-amino-acid modified GHRH analog. It resists DPP-IV degradation, extending half-life to about 30 minutes (No DAC) or days (DAC variant).
Receptor: Both bind the GHRH receptor (GHRHR) on anterior pituitary somatotrophs with similar affinity. The differences are in duration, not binding pathway.
Research history: Sermorelin has a longer published research history, including FDA-approved trial-based studies. CJC-1295 has more recent information on how the body uses its data and level-ranging human study data.
Sourcing standard: Both need HPLC purity above 99 percent. Mass spec check for research-grade lab use.

Here is a detailed side-by-side comparison of the two compounds across structure. How the body uses it, published research. Research selection criteria.

How Do Sermorelin and CJC-1295 Differ Structurally?

Sermorelin is GHRH(1-29)-NH2. It contains the first 29 amino acids of native GHRH with an amide group at the C-terminus. The amide change confers minimal half-life extension compared to the free acid form. The 29-amino-acid length is the shortest GHRH fragment that retains full GHRHR agonist action in studies. Native GHRH is 44 amino acids; the N-end 29 contain all residues needed for receptor link.

CJC-1295 adds a 30th amino acid and introduces change at positions 2. 8 that replace amino acids targeted by dipeptidyl peptidase IV (DPP-IV). DPP-IV cleaves the N-end bond that deactivates GHRH in circulation. By blocking this degradation site, CJC-1295 extends its active window. According to a structural comparison study in Peptides (2006), the change. The CJC-1295 half-life does not reduce GHRHR binding affinity since the modified residues are not part of the receptor contact surface.

How Do Half-Lives Compare Between the Two Compounds?

Sermorelin has a plasma half-life of under 10 minutes in rodent models. About 11 minutes in early humans how the body uses it studies. This short half-life produces a single GH pulse per use. Matching the natural pulsatile GHRH signaling pattern. experts use sermorelin when studying single-pulse GH dynamics or when lab design needs control over the precise timing of each GH boost event.

CJC-1295 No DAC extends this to about 30 minutes in lab models. The longer window produces a broader but still defined GH pulse. According to a pharmacokinetic comparison in Growth Hormone. IGF Research (2005). CJC-1295 No DAC produced greatly higher mean GH levels over four hours than sermorelin. Both were given at the same molar level in the same rodent model. The extended window rather than peak amplitude was the primary driver of the difference.

Browse fitness and GH peptides at Next Level Pharm for COA-tested Sermorelin, CJC-1295. Linked GHRH analog research compounds.

What Does the Published Research Show for Sermorelin?

Sermorelin has a longer published research history than CJC-1295. It was studied in FDA-controlled trial-based trials for GH deficiency in the 1990s. Received FDA approval as Geref (sermorelin acetate) for pediatric GH deficiency testing. The how the body uses it, receptor link. GH boost data from that control program constitute a well-characterized research baseline.

According to a clinical pharmacology study in the Journal of Clinical Endocrinology. Metabolism (1997), sermorelin produced clear GH pulses in pediatric and adult subjects with defined level-response relationships. IGF-1 responses tracked GH changes with expected hepatic lag times. The well-characterized level-GH response curve makes sermorelin a useful reference compound in GHRH research. Mainly in new study designs where experts need a known GH-stimulant comparator.

What Does the Published Research Show for CJC-1295?

CJC-1295 research is more recent than sermorelin. Includes key human how the body uses its data. According to a study in the Journal of Clinical Endocrinology. Metabolism (2006), a single use of CJC-1295 produced GH rise. IGF-1 increases lasting days in healthy adult subjects. This sustained response was unlike anything reported for sermorelin or native GHRH. Reflected the extended half-life produced by the DPP-IV-resistant change.

Lab rodent studies established the receptor link, GH level-response. IGF-1 kinetics that informed the human study design. CJC-1295’s well-documented level-GH relationship. Known structural differences from native GHRH make it a useful tool for experts who need a longer-acting GHRH model compound in GH axis research designs.

Which Compound Fits Which Research Design?

Sermorelin is better suited for study designs. It needs short, defined GH pulses with precise timing control. Its short half-life means each use produces one discrete GH boost event. experts studying GH pulse frequency, GH clearance kinetics. Or pulsatile IGF-1 dynamics benefit from sermorelin’s predictable narrow boost window.

CJC-1295 No DAC is better suited for study designs that need a broader GH boost window. It also suits designs needing a higher total GH area under the curve per use. Experts who combine CJC-1295 with ipamorelin in dual-receptor studies prefer its extended duration. The same applies to those studying downstream IGF-1 changes that need sustained GH rise. According to a study design review in Endocrine Reviews (2018). Selecting between GHRH analogs needs matching the way the body uses its profile to the exact GH dynamic. The choice depends on what the study is designed to capture.

What Quality Standards Apply to Both Compounds?

Both sermorelin and CJC-1295 need HPLC purity above 99 percent for research-grade use. HPLC separates truncated or modified variants that may co-elute with the correct peptide. For CJC-1295. Mass spec is mainly key since the DPP-IV-resistant change change the expected molecule weight from native GHRH. For sermorelin, mass spec confirms the 29-amino-acid chain. The C-end amide change that affects receptor link.

A lot-exact Certificate of Test records both analytical results with a traceable lot number. Experts who publish GH axis findings are expected to report sourcing with purity data. Lots of references in methods sections. This makes lot-level COA records a practical requirement beyond a quality standard alone.

Frequently Asked Questions

What is the difference between Sermorelin and CJC-1295?

Sermorelin is the 29-amino-acid N-end fragment of native GHRH with a plasma half-life under 10 minutes. CJC-1295 is a 30-amino-acid GHRH analog modified to resist DPP-IV degradation. Extending half-life to about 30 minutes (No DAC) or days (DAC variant). Both bind the GHRH receptor and boost pituitary GH release but produce different GH pulse durations.

How does Sermorelin work in research models?

Sermorelin binds the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells, triggering a cAMP signaling cascade. It boosts GH production and pulsatile release. Its 29-amino-acid chain includes all residues needed for GHRHR binding. The short half-life produces a single defined GH pulse per use. Matching natural pulsatile GHRH signaling dynamics.

How does CJC-1295 differ from Sermorelin in pharmacokinetics?

CJC-1295 modifies residues at positions 2. 8 to block DPP-IV cleavage, the enzyme that rapidly degrades native GHRH. This extends its half-life from under 10 minutes (sermorelin) to about 30 minutes (No DAC). A 2005 comparison studied how the body uses each peptide. Results showed CJC-1295 No DAC produced higher mean GH levels over four hours than sermorelin at the same molar level.

Which GHRH analog has more published research?

Sermorelin has a longer published research history, including FDA-controlled trial-based trials. An approved product (Geref) for GH deficiency testing. CJC-1295 research is more recent. Includes humans how the body uses its data from a 2006 trial-based study. Both have well-characterized level-GH response relationships in lab and trial-based contexts.

When would a researcher choose Sermorelin over CJC-1295?

Experts use sermorelin when studying single-pulse GH dynamics, GH clearance kinetics. Or when precise control over GH boost timing is needed. Its short half-life ensures each use produces one discrete GH event. CJC-1295 is preferred when extended GH boost is needed. Or when combining with ipamorelin in dual-receptor GH axis study designs.

What purity standard applies to research-grade Sermorelin and CJC-1295?

Both compounds need HPLC purity above 99 percent. Mass spec confirms the correct molecule weight. For CJC-1295, mass spec is mainly key. The DPP-IV-resistant change changes the expected molecule weight from native GHRH. For sermorelin, mass spec confirms the 29-amino-acid chain and C-end amide. A lot-exact COA records both results.

Are Sermorelin and CJC-1295 for human use?

The research-grade compounds are for lab research only. They are not approved for human use, therapeutic. Or diagnostic purposes outside of licensed trial-based trial settings. All published studies cited in this article used animal models or controlled early-phase research protocols. Neither compound should be used outside of an authorized research setting.

Where do Sermorelin and CJC-1295 ship from?

Research-grade Sermorelin and CJC-1295 ship to all 50 states within the United States. A Certificate of Test with HPLC purity data, mass spec results. Lot number ships with every order to provide full sourcing records for lab research.

Summary

Sermorelin and CJC-1295 are both GHRHR agonists that boost pituitary GH release in research models. Sermorelin mirrors native GHRH in structure. Half-life, producing short, defined GH pulses with a long published data history. CJC-1295 extends the active window through DPP-IV resistance. Producing a broader GH boost suitable for different research designs. Selection between the two depends on whether the study needs pulsatile or extended GH dynamics. Both need HPLC purity above 99 percent and lot-exact COA records for traceable research use.

What Should You Do Next?

Browse research-grade Sermorelin. CJC-1295 (No DAC) at Next Level Pharm for COA-tested options with full HPLC. Mass spec data on every batch.

About the Author

Next Level Pharm Research Team

Alex M covers peer-reviewed findings in peptide science for Next Level Pharm, a US-based supplier of research-grade peptides verified to >=99% purity via HPLC and mass spectrometry on every batch.

Disclaimer: The information provided on this page is for educational and research purposes only. Next Level Pharm’s products are intended for laboratory research use only. They are not intended for human consumption, diagnostic, therapeutic, or medicinal purposes. This content does not constitute medical advice. Always consult a licensed healthcare professional before making any health-related decisions.

Sermorelin vs CJC-1295: What Research Shows About Each GHRH Analog